2024年营收241亿元，益丰药房拟10派4元

Core Viewpoint - Yifeng Pharmacy reported stable financial performance with significant revenue and profit growth, while expanding its retail network and enhancing its digital capabilities [1][2][3] Financial Performance - In 2024, the company achieved an operating income of 24.062 billion yuan and a net profit attributable to shareholders of 1.529 billion yuan [1] - For Q1 2025, the company reported a revenue of 6.009 billion yuan and a net profit of 449 million yuan, reflecting a year-on-year growth of 10.51% [1] - The company plans to distribute a cash dividend of 4 yuan per 10 shares, totaling approximately 485 million yuan, which represents 51.56% of the annual net profit [1][5] Store Expansion - Yifeng Pharmacy has been actively expanding its store network, reaching a total of 14,684 stores by the end of 2024, a year-on-year increase of 10.82% [2] - The company has developed a diverse store layout, including flagship stores, regional centers, and community pharmacies, while also focusing on the DTP pharmacy model and 24-hour service pharmacies [2] Digital Innovation - The company has launched five intelligent warehouse projects to enhance logistics efficiency, with the Suqian distribution center officially starting operations by the end of 2024 [3] - Yifeng Pharmacy has developed multiple smart retail channels, including B2C, O2O, and mobile applications, with over 10,000 O2O direct-operated stores online by the end of 2024 [2] ESG Performance - Yifeng Pharmacy received an MSCI-ESG rating upgrade from BB to A, becoming the only chain pharmacy in China with an A rating or above [3][4] - The company has made significant progress in environmental responsibility, saving 1.46 million kWh of electricity in 2024 and achieving 100% photovoltaic power generation at its headquarters [4]